<?xml version="1.0" encoding="UTF-8"?>
<eudamedExport entity="devices">
  <row>
    <udiDi>06420615711063</udiDi>
    <basicUdiDi>642061571360072BK</basicUdiDi>
    <tradeName>Terveyskaista HOIVA Makrogoli 4000 Suolaton 10x12 g</tradeName>
    <deviceName>MACROGOL</deviceName>
    <manufacturerName>Galena Pharma Oy</manufacturerName>
    <manufacturerSrn>FI-MF-000000588</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>503009</reference>
    <placedOnMarketCountry>Finland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T14:37:55.430Z</lastUpdated>
  </row>
  <row>
    <udiDi>05944732019112</udiDi>
    <basicUdiDi>5944732DEFOAMINGEQ</basicUdiDi>
    <tradeName>05944732019112</tradeName>
    <deviceName>Assista Simeticona Baby, emulsie</deviceName>
    <manufacturerName>Fiterman Pharma SRL</manufacturerName>
    <manufacturerSrn>RO-MF-000001410</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>ASSB em50</reference>
    <placedOnMarketCountry>Romania</placedOnMarketCountry>
    <lastUpdated>2026-07-31T13:16:32.661Z</lastUpdated>
  </row>
  <row>
    <udiDi>05904055005179</udiDi>
    <basicUdiDi>5904055002ZSEP</basicUdiDi>
    <tradeName>Ulgix Wzdęcia Baby</tradeName>
    <deviceName>Emulsja doustna z symetykonem ze strzykawką dozującą</deviceName>
    <manufacturerName>Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A.</manufacturerName>
    <manufacturerSrn>PL-PR-000009265</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>Not applicable</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-31T10:24:20.143Z</lastUpdated>
  </row>
  <row>
    <udiDi>05904055002871</udiDi>
    <basicUdiDi>5904055001KQ3</basicUdiDi>
    <tradeName>ULGIX WZDĘCIA MAX</tradeName>
    <deviceName>Kapsułki miękkie z symetykonem (Soft capsules with simethicone)</deviceName>
    <manufacturerName>Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A.</manufacturerName>
    <manufacturerSrn>PL-MF-000009264</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>-</reference>
    <placedOnMarketCountry>Poland</placedOnMarketCountry>
    <lastUpdated>2026-07-31T10:24:15.353Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778108184</udiDi>
    <basicUdiDi>42517781MD347D7</basicUdiDi>
    <tradeName>DulcoSoft</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf IIb</riskClass>
    <legislation>UNKNOWN</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>795089</reference>
    <placedOnMarketCountry>Ireland</placedOnMarketCountry>
    <lastUpdated>2026-07-30T22:07:42.065Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106234</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571308</reference>
    <placedOnMarketCountry>Germany</placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:38:12.714Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106241</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.998Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106258</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>1571373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.966Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106265</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.908Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106272</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.838Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106289</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>572373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.764Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106296</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>573308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.713Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106302</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>573391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.686Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106319</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>573373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.645Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106326</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>574308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.586Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106333</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>574391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.552Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106340</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>574373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.514Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106357</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>314571308</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.483Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106364</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>314571391</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.451Z</lastUpdated>
  </row>
  <row>
    <udiDi>04251778106371</udiDi>
    <basicUdiDi>42517781MD339D8</basicUdiDi>
    <tradeName>Refluthin</tradeName>
    <deviceName></deviceName>
    <manufacturerName>HÄLSA Pharma GmbH</manufacturerName>
    <manufacturerSrn>DE-MF-000007407</manufacturerSrn>
    <authorisedRepresentativeName></authorisedRepresentativeName>
    <authorisedRepresentativeSrn></authorisedRepresentativeSrn>
    <riskClass>Sınıf III</riskClass>
    <legislation>MDR 2017/745</legislation>
    <emdnCode>G0401</emdnCode>
    <emdnDescription>ORALLY ADMINISTERED DEVICES FOR THE THERAPY OF GASTRO-INTESTINAL DISORDERS</emdnDescription>
    <deviceStatus>Piyasada</deviceStatus>
    <reference>314571373</reference>
    <placedOnMarketCountry></placedOnMarketCountry>
    <lastUpdated>2026-07-29T23:29:42.415Z</lastUpdated>
  </row>
</eudamedExport>